-
The CHS board is recruiting!
The CHS Board of Directors is a skills-based board meaning it is composed of individual skills, expertise, qualifications and personal characteristics. In 2023, multiple Board of Director positions are...
Running a marathon in record time with severe hemophilia A
by James Bayford – Kelowna, British Columbia “Why?” Is a question I asked myself as I laced up my running shoes before a scheduled 20 mile (32 km) training...
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A in adult patients with...
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene dezaparvovec has been given...
INNOVATORS
BUILDER
Believers
